In The News
Richmond Times-Dispatch | September 28, 2016
ImmunArray, a molecular diagnostics company with an office in the Virginia Biotechnology Research Park in Richmond, announced it has received an investment from Quanterix to advance its work in traumatic head injury research.
Multiple Sclerosis News Today | November 17, 2016
Quanterix and UmanDiagnostics are working to advance an assay capable of detecting neuron damage in a blood sample
Science | January 6, 2017
In athletes who suffered a concussion, a protein in their blood may be able to predict when they can return to action.
Bloomberg Businessweek | February 1, 2017
Quanterix is one of several life sciences companies racing for a way to diagnose CTE in the living.
Helio | February 16, 2017
The blood neurofilament light chain protein can be used to distinguish Parkinson’s disease from atypical parkinsonism disorders such as multiple system atrophy, progressive supranuclear palsy and corticobasal degeneration, according to research recently published in Neurology.
MedPage Today | March 28, 2017
Neurofilament light levels correlated with mental deficits but short on specificity